Healthcare Industry News: Insulet
News Release - September 13, 2010
OrbiMed Expands Private Equity TeamNEW YORK--(Healthcare Sales & Marketing Network)--OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce that Vince Burgess, Peter Thompson, M.D., and Joseph Zakrewski have joined the firm as Venture Partners, and that Alexander Cooper has joined the firm as General Counsel.
In their new roles, Mr. Burgess, Dr. Thompson, and Mr. Zakrewski will contribute their extensive experience and expertise as they collaborate with OrbiMed's global team of approximately 40 investment professionals to invest in healthcare companies across all stages of development. As General Counsel, Mr. Cooper will be responsible for leading OrbiMed's legal and compliance affairs.
Vince Burgess brings over 20 years of experience in healthcare operations, business development and venture capital investment to OrbiMed. Mr. Burgess was on the founding executive team at Volcano Corp., where he was Group President, Advanced Imaging Systems, and also led global marketing and business development from 2002 to 2010. At Volcano, he was a key architect of the company's product, marketing and M&A/partnering strategies. During his tenure, Volcano grew from a raw start-up to a global company with over 1,000 employees and a market capitalization of over $1.2 billion. Previously, Mr. Burgess served as a general partner of San Diego-based Sorrento Ventures, focusing on the firm's healthcare investments. Mr. Burgess also has prior operational and board level experience in the surgical tool, ophthalmology and health care IT fields. Mr. Burgess earned his MBA at the Anderson School at UCLA and his BS in Business Administration from USC.
Peter Thompson, M.D., brings over 20 years of industry experience to OrbiMed. He co-founded Trubion Pharmaceuticals, and served as CEO and Chairman from its inception through its IPO on NASDAQ and as a public company until his retirement in 2009. Dr. Thompson is the former Vice President & General Manager of Chiron Informatics at Chiron Corporation and held various executive positions at Becton Dickinson, including Vice President, Research and Technology Department of BD Bioscience. Dr. Thompson is a co-founder of iMetrikus, a clinical decision support company, where he served as CEO and Chairman. He is the founder and Managing Director of Strategicon Partners, an investment and management services company. He currently serves as a Director of CoDa Therapeutics and Response Biomedical. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, a board-certified internist and oncologist, and was on staff at the National Cancer Institute following his internal medicine training at Yale University. Dr. Thompson received Sc.B. and M.D. degrees from Brown University.
Joseph S. Zakrzewski was most recently the President and Chief Executive Officer of Xcellerex, a privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and vaccines. Mr. Zakrzewski also served as the Chief Operating Officer of Reliant Pharmaceuticals, a specialty pharmaceutical company focused on cardiovascular drugs. Reliant Pharmaceuticals was sold to GlaxoSmithKline in 2007. From 1988 to 2004, Mr. Zakrzewski served in a variety of executive level capacities at Eli Lilly & Company including R&D, manufacturing, finance and business development. His most recent position was Vice President, Corporate Business Development, where he had global responsibility for all business development activities on a global basis. Mr. Zakrzewski received a BS in Chemical Engineering in 1986, an MS in Biochemical Engineering from Drexel University in 1988, and received an MBA in Finance in 1992 from Indiana University. Mr. Zakrzewski also serves on the Boards of Insulet Corporation and Rapid Micro, and Chairman of the Boards of Directors of Amarin Corp, Promedior Inc, Xcellerex Inc., and Zelos Therapeutics.
Alexander M. Cooper joins OrbiMed from Goldman Sachs, where he served as counsel primarily in the Asset Management business and also in the Corporate Governance group. Prior to Goldman Sachs, he was an attorney at Davis Polk & Wardwell in the Investment Management Group and Litigation Department. Mr. Cooper received his J.D. from Yale Law School, as well as an M.Phil. from Oxford University and an A.B., magna cum laude and Phi Beta Kappa, from Brown University.
OrbiMed is a preeminent investment firm dedicated exclusively to the healthcare sector, with approximately $5 billion in assets under management. OrbiMed invests across the entire spectrum of pharmaceutical, biotechnology and medical device companies on a worldwide basis. Investments are made through venture capital funds, hedge funds, and other investment vehicles.
Since inception of its venture capital activities in 1993, OrbiMed has partnered with over 100 companies across a wide range of therapeutic categories and stages of development. OrbiMedís investment team includes approximately 40 experienced professionals with offices in New York City, San Francisco, Shanghai and Mumbai. As the largest investment firm dedicated to the healthcare sector, OrbiMed is a capital provider of choice, bringing the global resources required to be an exceptional long term partner for building world-class biopharmaceutical and medical technology companies. www.OrbiMed.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.